why choose us

First received: July 31, 2023

Clinical Trial: RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Muscle Invasive Bladder Cancer

Study Type: INTERVENTIONAL


Official Title: RC48 Combined With PD-1 and Radiotherapy as Bladdersparing Therapy in Patients With Muscular Infiltrating Bladder Uroepithelial Carcinoma With Limited HER-2 Expression Following Maximum Electrical Res

Brief Summary: This is a prospective, open, single-center clinical study of RC48 combined with PD-1 and radiotherapy as bladder-preserving therapy in patients with muscular invasive bladder uroepithelial carcinoma with high HER-2 expression (IHC 2+ or 3+).The study was conducted in accordance with the Good Practice for Clinical Trials of Pharmaceutical Products (GCP).Six patients were enrolled in this study.Each patient received RC48 injection [2.0 mg/kg, Q2W, iv] and Toripalimab injection [3mg/kg, Q2W, iv] for 1~2…

Read more